Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
Company Details
- Employees
- 15
- Founded
- -
- Address
- Epfl Innovation Park, Bâtiment B,switzerland
- in****@****ron.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- asceneuron.com
- Keywords
- Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology.
- HQ
- Lausanne, Vaud
Asceneuron Sa Questions
Asceneuron Sa's website is asceneuron.com
Asceneuron Sa's LinkedIn profile is https://ch.linkedin.com/company/asceneuron-sa
Asceneuron Sa has
15 employees.
View email and phone details for 15
employees at Asceneuron Sa.
Asceneuron Sa's industry is
Biotechnology Research
Asceneuron Sa's top competitors are
Neo Medical,
Skycell Ag,
Bright Peak Therapeutics,
Alentis Therapeutics,
Atlas Agro,
Terralayr,
Neustark,
Ionctura,
Distalmotion,
Mindmaze.
Asceneuron Sa's support email address is info@asceneuron.com
Asceneuron Sa's categories are Biotechnology Research
Asceneuron Sa's founding year is 2012
